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OBJECTIVE—Despite tremendous progress in vitreoretinal sur-
gery, certain postsurgical complications limit the success in the
treatment of proliferative vitreoretinal diseases (PVDs), such as
proliferative diabetic retinopathy (PDR) and proliferative vitreo-
retinopathy (PVR). One of the most signiﬁcant complications is
the cicatricial contraction of proliferative membranes, resulting
in tractional retinal detachment and severe vision loss. Novel
pharmaceutical approaches are thus urgently needed for the
management of these vision-threatening diseases. In the current
study, we investigated the inhibitory effects of statins on the
progression of PVDs.
RESEARCH DESIGN AND METHODS—Human vitreous con-
centrations of transforming growth factor-2 (TGF-2) were
measured by enzyme-linked immunosorbent assay. TGF-2– and
vitreous-dependent phosphorylation of myosin light chain
(MLC), a downstream mediator of Rho-kinase pathway, and
collagen gel contraction simulating cicatrical contraction were
analyzed using cultured hyalocytes. Inhibitory effects of simva-
statin on cicatrical contraction were assessed both in vitro and in
vivo.
RESULTS—Human vitreous concentrations of TGF-2 were
signiﬁcantly higher in the samples from patients with PVD
compared with those without PVD. Simvastatin inhibited TGF-
2–dependent MLC phosphorylation and gel contraction in a
dose- and time-dependent manner and was capable of inhibiting
translocation of Rho protein to the plasma membrane in the
presence of TGF-2. Vitreous samples from patients with PVD
enhanced MLC phosphorylation and gel contraction, whereas
simvastatin almost completely inhibited these phenomena. Fi-
nally, intravitreal injection of simvastatin dose-dependently pre-
vented the progression of diseased states in an in vivo model
of PVR.
CONCLUSIONS—Statins might have therapeutic potential in
the prevention of PVDs. Diabetes 57:2784–2793, 2008
P
roliferative vitreoretinal diseases (PVDs), such as
proliferative diabetic retinopathy (PDR) and pro-
liferative vitreoretinopathy (PVR), are common
causes of severe vision loss (1). Surgical ap-
proaches for the treatment of these diseases have evolved
signiﬁcantly in the recent past, but the occurrence of
postoperative complications, such as cicatricial contrac-
tion, limit the therapeutic success (2). Therefore, there is
an urgent need for alternate pharmacological treatments
of PVDs that can complement or potentially replace sur-
gical intervention. In PDR and PVR, excessive wound
healing and ﬁbrosis induce the formation of proliferative
membranes on the retinal surface. The proliferative mem-
brane then extends into the vitreous and contracts, caus-
ing tractional detachment (3). The proliferative membrane
consists of various cells, including hyalocytes, retinal
pigment epithelial cells, glial cells, and ﬁbroblast-like cells
(4–7).
Hyalocytes morphologically resemble macrophages and
are considered to originate from peripheral blood mono-
cytes (8). Under physiological conditions, hyalocytes are
mainly located in the cortical vitreous and are considered
to maintain its transparency (9,10). Under pathological
conditions, hyalocytes are thought to be critical in vitreo-
retinal interface diseases, such as idiopathic epiretinal
membrane formation, macular hole, and diabetic macular
edema (11). Hyalocytes in diabetic eyes are higher in
number and of different shape compared with those in
normal eyes (12).
Transforming growth factor- (TGF-) is pivotal to
tissue ﬁbrosis. Among the three isoforms of TGF-,
TGF-2 is the predominant isoform in the vitreous (13,14).
We and others have shown that TGF-2 is overexpressed
in the epiretinal membrane and vitreous of PDR and PVR
patients and that its expression correlates with the pres-
ence of intraocular ﬁbrosis (14–17). TGF-2 modulates the
differentiation of various cell types and is considered to
increase the production of extracellular matrix, resulting
in the formation and contraction of proliferative mem-
branes (18,19). Thus, it is possible that the combination of
hyalocytes and TGF-2 may contribute to the pathogene-
sis of PVDs.
Statins, inhibitors of the 3-hydroxy-3-methyl-glutaryl
(HMG)-CoA reductase, are widely used to reduce endoge-
nous cholesterol synthesis and improve hypercholesterol-
emia (20). HMG-CoA reductase is an upstream enzyme in
the mevalonate biosynthetic pathway that catalyzes the
conversion of HMG-CoA into mevalonate and then, in a
number of steps, into farnesylpyrophosphate (FPP), a
precursor of cholesterol (21). By inhibiting HMG-CoA
reductase, statins block the mevalonate pathway, resulting
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2784 DIABETES, VOL. 57, OCTOBER 2008in reduced synthesis of FFP and cholesterol. Statins are
divided into three categories: the natural (i.e., lovastatin
and pravastatin), the semisynthetic (i.e., simvastatin), and
the synthetic (i.e., atorvastatin, ﬂuvastatin, and cerivasta-
tin). Statins decrease the risk for cardiovascular events
even among high-risk individuals with coronary disease
and diabetes (22). Moreover, statins may be useful in the
treatment of other conditions, such as osteoporosis (23)
and cancer growth and metastasis (24,25).
Another product of the mevalonate pathway is gera-
nylgeranylpyrophosphate (GGPP), which is synthesized
from FPP. Both FPP and GGPP are important isoprenoid
intermediates and serve as lipid attachments for a variety
of intracellular proteins to the plasma membrane, includ-
ing the -subunit of heterotrimeric G-proteins and the
small GTP-binding proteins, such as Ras and Rho, result-
ing in their activation (26). Rho translocation from the
cytoplasm to the plasma membrane is dependent on
geranylgeranylation (GGPP attachment), whereas Ras
translocation is dependent on farnesylation (FPP attach-
ment) (27). Rho in the plasma membrane is implicated in
the cytoskeletal responses to extracellular signals and is
converted to an active GDP-bound state (28). Rho-kinase,
one of the effector molecules of Rho, is involved in a
variety of cellular events related to cell morphology,
adhesion, and motility (28–30), especially through phos-
phorylation of the myosin light chain (MLC). MLC phos-
phorylation induces actin-myosin interaction and,
consequently, smooth muscle contraction and stress ﬁber
formation in nonmuscle cells (31,32). Activation of the
Rho/Rho-kinase pathway is therefore indispensable for
smooth muscle contraction. GGPP is one of the down-
stream components of the mevalonate pathway and plays
an important part in the Rho/Rho-kinase pathway activa-
tion. Thus, statins, which regulate the mevalonate path-
way, also regulate the Rho/Rho-kinase pathway and,
consequently, MLC phosphorylation.
Previously, we reported that the Rho-kinase pathway is
involved in TGF-2–induced MLC phosphorylation and
contraction of hyalocyte-containing collagen gels and that
hydroxyfasudil, a potent Rho-kinase inhibitor, signiﬁcantly
diminishes these TGF-2–induced effects (18). In the
present study, we investigate the regulatory effects of
statins on TGF-2– and vitreous-dependent MLC phos-
phorylation and contraction of hyalocyte-containing colla-
gen gels and their therapeutic potential for prevention of
PVDs in vivo.
RESEARCH DESIGN AND METHODS
Reagents. Simvastatin, ﬂuvastatin, pravastatin, and cerivastatin were pur-
chased from CalBiochem (La Jolla, CA). Lovastatin was purchased from
Funakoshi (Tokyo). Simvastatin was used as an active form after treatment
with NaOH.
Vitreous samples and enzyme-linked immunosorbent assay. This study
was carried out with approval from the Institutional Review Board and
performed in accordance with the ethical standards of the 1989 Declaration of
Helsinki. We obtained written informed consent from the patients. Vitreous
samples were collected from patients who underwent pars plana vitrectomy
because of non-PVD (macular hole) or PVD (PDR and PVR). Concentrations
of TGF-2 were measured by a human TGF-2 immunoassay kit (R&D
Systems, Minneapolis, MN).
Cell culture. Bovine hyalocytes were isolated as we previously reported (33).
Cultured hyalocytes obtained between passages 5 and 7 were used in
experiments.
Collagen gel contraction assay. The contraction assay was performed as
we previously described (33). Type I collagen (Koken, Tokyo), a reconstitu-
tion buffer, hyalocytes suspension, and distilled water were mixed and added
to a 24-multiwell plate (Nunc, Roskilde, Denmark). After 1-h pretreatment of
vitreous samples with 1 g/ml anti–TGF-2 antibody (R&D Systems) or 1
g/ml mouse IgG (Sigma-Aldrich) that was added for conﬁrming the absence
of nonspeciﬁc suppression of the gel contraction by anti–TGF-2 antibody,
the gels were treated with the vitreous samples (400 l). The diameter of the
collagen gel was measured at 5 days after the treatment. For quantitative
purposes, contraction data are presented as the reduction in diameter of the
collagen gels.
In the same way, collagen gels containing hyalocytes were starved,
pretreated with statins for 24 h, and then treated with 3 ng/ml TGF-2
(Sigma-Aldrich) or vitreous samples.
Western blot analysis. Total cell lysates were subjected to 15% SDS-PAGE,
and the blots were incubated with an antibody against phosphorylated-MLC
(p-MLC; 1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA). Visualization was
performed with an enhanced chemiluminesence (ECL; Amersham, Arlington
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FIG. 1. TGF-2 expression in the vitreous. A: Vitreous samples were
collected from patients with non-PVD (macular hole) and PVD (PDR
and PVR). Concentrations of TGF-2 in the vitreous were measured by
enzyme-linked immunosorbent assay (macular hole, n  27; PDR, n 
53; PVR, n  22). **P < 0.01 compared with macular hole. B: Hyalocytes
were embedded in type I collagen gels (n  4). After starvation and
pretreatment with 1 g/ml anti–TGF-2 antibody or 1 g/ml IgG for 1 h,
the collagen gels were treated with vitreous samples from patients
with PVD. Five days after the treatment, the gels were photographed.
C: The diameter of the collagen gels was measured and expressed as
percentage of the average diameter of the control group. *P < 0.05.
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reblotting the membranes with an antibody against MLC (Santa Cruz)
(1:1,000).
Plasma membrane proteins from the cells were isolated by Qproteome
Plasma Membrane Protein kit (Qiagen, Hilden, Germany) and were subjected
to Western blot analysis with an antibody against Rho (1:1,000; Upstate,
Charlottesville, VA).
Counting viable cells in collagen gels. After 5 days of treatment, the
collagen gels were dissolved by collagenase, and the cell suspension was
collected. The viable cell number was counted with hemocytometer after
trypan blue staining.
In vivo model of PVR. All experimental procedures using animals adhered to
the Association for Research in Vision and Ophthalmology Resolution on the
Use of Animals in Ophthalmic and Vision Research. We caused experimental
PVR in rabbit eyes as previously described (34). Homologous conjunctival
ﬁbroblasts were prepared by harvesting the conjunctival tissue. Twenty eyes
from 20 Dutch rabbits weighing 2–2.5 kg were assigned into three groups, and
ﬁbroblasts (100,000 cells) were injected into the right eye in each rabbit. Eyes
in the ﬁrst group (six eyes) were administered an intravitreal injection of 0.1
ml vehicle (balanced salt solution). Eyes in the second group (seven eyes)
were administered an intravitreal injection of 0.1 ml vehicle containing
simvastatin (5 mol/l ﬁnal intravitreal concentration). Eyes in the last group
(seven eyes) were administered an intravitreal injection of 0.1 ml vehicle
containing simvastatin (15 mol/l ﬁnal intravitreal concentration). The clinical
observations were performed carefully as long as 28 days after surgery and
categorized according with the PVR classiﬁcation of Fastenberg et al. (35).
Electroretinography. Nine eyes from 10 Dutch rabbits weighing 2–2.5 kg
were assigned into three groups. Eyes in the ﬁrst group (three eyes) were
administered an intravitreal injection of 0.1 ml vehicle. Eyes in the second
group (three eyes) were administered an intravitreal injection of 0.1 ml vehicle
containing simvastatin (5 mol/l ﬁnal intravitreal concentration). Eyes in the
third group (three eyes) were administered an intravitreal injection of 0.1 ml
vehicle containing simvastatin (15 mol/l ﬁnal intravitreal concentration).
Electroretinogram was performed on day 28 as previously described (36).
Light microscopy. The eyes were enucleated and ﬁxed in 4% paraformalde-
hyde on day 28. Whole eyes were cut approximately along the vertical
meridian. Parafﬁn-embedded sections were stained with hematoxylin-eosin,
and each section was examined using light microscopy.
TdT-dUTP terminal nick-end labeling assay. Apoptotic and potentially
necrotic cell death was detected by TdT-dUTP terminal nick-end labeling
(TUNEL). The eyes were ﬁxed in 4% paraformaldehyde and embedded in
parafﬁn. TUNEL staining was performed with the TdT Fluorescein in situ
apoptosis detection kit (R&D Systems), according to the manufacturer’s
protocols. The sections were costained with propidium iodide (Molecular
Probes, Eugene, OR) to observe the cell nuclei by ﬂuorescence microscopy
(KEYENCE, BIORAVO, and BZ-9000). As a TUNEL-positive control, we used
the retina of rabbit PVR model on day 7 after the onset.
Transmission electron microscopy. The eyes were ﬁxed in 1% glutaralde-
hyde and 1% paraformaldehyde in PBS. The specimens were postﬁxed in
veronal acetate buffer osmium tetroxide (2%), dehydrated in ethanol and
water, and embedded in Epon. Ultrathin sections were cut from blocks and
mounted on copper grids. The specimens were observed with an electron
microscope (H7650; Hitachi, Tokyo).
Statistical analysis. Statistical differences were assessed using nonparamet-
ric test (Kruskal-Wallis variance analysis) for the data of TGF-2 concentra-
tions and ANOVA for the other groups. P values 0.05 were considered
signiﬁcant. To adjust for inﬂated -error due to multiple comparisons, the
corrected signiﬁcant P value was deﬁned using the Bonferroni correction.
RESULTS
TGF-2 in the vitreous and its impact on membrane
contraction. The median TGF-2 protein concentrations,
2.35 ng/ml (range 0.72–5.26) in macular hole (n  27), 4.74
ng/ml (1.60–13.0) in PDR (n  53), and 4.48 ng/ml (2.52–
21.6) in PVR (n  22) patients, were signiﬁcantly higher in
PDR or PVR patients than in patients with macular hole
(P  0.01) (Fig. 1A). The median TGF-2 protein concen-
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FIG. 2. Inhibitory effect of simvastatin on TGF-2–dependent MLC phosphorylation. Hyalocytes were starved in Dulbecco’s modiﬁed Eagle’s
medium containing 3% calf serum for 24 h. A: Hyalocytes were pretreated for 30 min with or without the indicated concentrations of simvastatin
(0.3, 1, 3, and 10 mol/l) and subsequently treated with 3 ng/ml TGF-2 for 24 h. Total cell lysates were subjected to Western blot analysis with
an antibody against p-MLC. Lane loading differences were normalized by reblotting the membranes with an antibody against MLC. C: Hyalocytes
were pretreated with or without 5 mol/l simvastatin for the indicated time (1, 4, 10, and 24 h) and subsequently treated with 3 ng/ml TGF-2
for 24 h. p-MLC and MLC were also examined in the same way as in Fig. 1A. B and D: Signal intensity ratios (p-MLC to MLC) were expressed as
percentage of control intensity ratio. *P < 0.05 compared with TGF-2 alone.
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PVR showed no signiﬁcant difference (P  0.6).
Vitreous samples from patients with PVD and those
containing nonspeciﬁc IgG induced signiﬁcant contraction
of hyalocyte-containing collagen gels (63 and 67% vs.
control, respectively). In comparison, the vitreous-induced
contraction was virtually suppressed by speciﬁc anti–
TGF-2 antibody (P  0.05) (97% vs. control) (Fig. 1B and
C), suggesting a key role for TGF-2 in the vitreous-
induced collagen gel contraction.
Role of simvastatin in TGF-2–dependent MLC phos-
phorylation. TGF-2 enhanced MLC phosphorylation to
about two times that seen with control (Fig. 2A and B).
TGF-2–dependent MLC phosphorylation showed a signif-
icant reduction at 0.3 mol/l simvastatin or higher concen-
trations (up to 10 mol/l simvastatin) compared with
TGF-2 alone (P  0.05). The level of MLC phosphoryla-
tion at 10 mol/l simvastatin concentration was lower than
in untreated control, suggesting that simvastatin at higher
concentrations may block the constitutive level of MLC
phosphorylation. Because 3 mol/l simvastatin was sufﬁ-
cient to reverse the effect of TGF-2 on MLC phosphory-
lation, we chose the slightly higher concentration of 5
mol/l to study the time-dependent effect of simvastatin
on TGF-2–dependent MLC phosphorylation. Treatment
of the hyalocytes with 5 mol/l simvastatin for1ho r
longer (up to 24 h) signiﬁcantly suppressed the MLC
phosphorylation compared with TGF-2 alone, and treat-
ment with 5 mol/l simvastatin for 24 h sufﬁciently sup-
pressed the MLC phosphorylation below that of untreated
control (Fig. 2C and D).
TGF-2–dependent collagen gel contraction and its
inhibition by simvastatin. The control gels showed no
apparent contraction up to 5 days, whereas TGF-2
caused substantial collagen gel contraction in a time-
dependent manner in the ﬁrst 5 days (57.6% vs. control).
TGF-2–dependent collagen gel contraction was signiﬁ-
cantly reduced by simvastatin starting at a concentration
of 1 mol/l, and the reduction was greater at 3 and 10
mol/l (92 and 100% vs. control, respectively) (Fig. 3).
TGF-2–dependent Rho translocation to the plasma
membrane and its inhibition by simvastatin. TGF-2
signiﬁcantly enhanced the Rho translocation to the plasma
membrane (P  0.05), whereas simvastatin suppressed the
translocation (Fig. 4A and B). However, the effect of
simvastatin was reversed in the presence of 400 mol/l
mevalonate, a component of the mevalonate pathway.
These ﬁndings suggest that simvastatin inhibits Rho/Rho
kinase pathway by preventing Rho from translocating to
the plasma membrane via inhibition of the mevalonate
pathway.
Comparison of the effects of various statins on TGF-
2–dependent MLC phosphorylation and collagen gel
contraction. Simvastatin and ﬂuvastatin signiﬁcantly sup-
pressed TGF-2–dependent MLC phosphorylation by hya-
locytes, whereas pravastatin did not show an effect (Fig.
5A and B). In addition, simvastatin signiﬁcantly sup-
pressed MLC phosphorylation compared with ﬂuvastatin
(P  0.05). Next, we compared the inhibitory effect of
statins on the contraction of hyalocyte-containing collagen
gels. Simvastatin and ﬂuvastatin signiﬁcantly suppressed
TGF-2–dependent contraction of collagen gel, whereas
A
control
TGF-β2
01 3 10 0.3
( SS, μM )
B
%
 
d
i
a
m
e
t
e
r
 
V
S
 
c
o
n
t
r
o
l
0
20
40
60
80
100
120
control 0 0.3 1 3 10
*
*
*
(%)
NS
(SS, μM)
TGF-β2 
FIG. 3. The effect of simvastatin on TGF-2–induced contraction of
hyalocyte-containing collagen gels. Hyalocytes were embedded in type
I collagen gels (n  4). A: After starvation and pretreatment with
indicated concentrations of simvastatin for 24 h, the collagen gels were
stimulated with 3 ng/ml TGF-2. Five days after the stimulation, the
gels were photographed. B: The diameter of the collagen gels was
measured and expressed as a percentage of the average diameter of
control group. *P < 0.05; NS, not signiﬁcant compared with TGF-2
alone.
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FIG. 4. Inhibitory effect of simvastatin on the Rho translocation to the
plasma membrane. A: Hyalocytes were pretreated with 5 mol/l simva-
statin with or without mevalonate (Mev) and then treated with 3 ng/ml
TGF-2 for 24 h. Plasma membrane proteins were isolated and sub-
jected to Western blot analysis with an antibody against Rho. B: Signal
intensities were expressed as percentage of control intensity. *P <
0.05.
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addition, the inhibitory effect of simvastatin (100% vs.
control) was signiﬁcantly higher than that by ﬂuvastatin
(94% vs. control) (P  0.05). To test whether cytokine
and/or statin treatment affected the growth and/or viability
of the cells in our experiments, we treated the collagen
gels with collagenase and counted the number of viable
cells. Both TGF-2 and statins showed no signiﬁcant
effects on cell number in the three-dimensional collagen
gels (Fig. 5E).
Impact of simvastatin on MLC phosphorylation and
collagen gel contraction induced by vitreous samples
from patients with PVD. Vitreous samples from patients
with PVD caused a signiﬁcantly larger enhancement of
MLC phosphorylation than those from patients with non-
PVD (Fig. 6A and B). Simvastatin (5 mol/l) strongly
attenuated the vitreous-induced MLC phosphorylation. Ex-
pression of GAPDH did not change after the treatment
with simvastatin or stimulation with vitreous samples.
However, total MLC increased in cells stimulated with the
vitreous samples compared with cells without vitreous
treatment, and the increase was larger in cells stimulated
with vitreous samples from patients with PVD than those
from patients without PVD. These increases in an amount
of total MLC were suppressed by 5 mol/l simvastatin.
The contraction of hyalocyte-containing collagen gels
stimulated with the vitreous samples from patients with
PVD was signiﬁcantly larger compared with the contrac-
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FIG. 5. Comparison of inhibitory effects of simvastatin, ﬂuvastatin, and pravastatin on TGF-2–dependent MLC phosphorylation and collagen gel
contraction. A: Starved hyalocytes were pretreated with vehicle, 5 mol/l simvastatin, ﬂuvastatin, or pravastatin for 30 min and subsequently
treated with or without 3 ng/ml TGF-2 for 24 h. Total cell lysates were subjected to Western blot analysis with an antibody against p-MLC. Lane
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expressed as percentage of intensity ratio of vehicle alone. *P < 0.05. C: Hyalocytes were embedded in type I collagen gels (n  4). After
starvation and pretreatment with vehicle, 5 mol/l simvastatin, ﬂuvastatin, or pravastatin for 24 h, the collagen gels were stimulated with 3 ng/ml
TGF-2. Five days after the stimulation, the gels were photographed. D: The diameter of the collagen gels was measured and expressed as
percentage of the average diameter of control group. **P < 0.01, *P < 0.05; NS, not signiﬁcant. E: The viable cell number in the collagen gels was
counted to exclude the effect of cell growth or cytotoxicity on the collagen gel contraction or its inhibition. Five days after the treatment, the
collagen gels were dissolved, and the cell suspension was collected. The viable cell number was counted with hemocytometer after trypan blue
staining (n  4; NS, not signiﬁcant compared with control).
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patients without PVD (P  0.05) (Fig. 6C and D). We
further examined the inhibitory effect of simvastatin on
vitreous-dependent contraction of collagen gels and found
that 5 mol/l simvastatin suppressed the collagen gel
contraction induced by vitreous samples even from pa-
tients with PVD.
Simvastatin inhibition of PVR development in vivo.
The control eyes of rabbits injected with vehicle devel-
oped PVR and were accompanied by proliferative mem-
brane formation and cicatricial contraction, resulting in
tractional retinal detachment (Fig. 7A). In comparison, 5
and 15 mol/l simvastatin (ﬁnal intravitreal concentra-
tions) signiﬁcantly prevented PVR development (Fig. 7C).
Simvastatin inhibited the contraction of the proliferative
membrane, and the membranes in eyes treated with sim-
vastatin were much thinner than those in vehicle-treated
eyes (Fig. 7B). After simvastatin injections were stopped
at day 7, the eyes treated with 5 mol/l simvastatin
developed a mild but signiﬁcant PVR, whereas no signiﬁ-
cant PVR development was observed in the eyes treated
with 15 mol/l simvastatin.
Absence of apparent adverse effects of simvastatin in
the retina. To evaluate the retinal function after intravit-
real application of simvastatin, we performed electroreti-
nography. The mean amplitude and latency of the 2Hz b
wave in the eyes treated with 5 or 15 mol/l simvastatin
were 203.4 V and 28.1 ms and 201.7 V and 28.4 ms,
respectively, and were not signiﬁcantly different from
those without any treatment or those of the vehicle-treated
eyes (204.8 V and 28.1 ms), suggesting that at these
concentrations, simvastatin may not impede retinal func-
tion (Fig. 8A).
The histological structure of the retina in the eyes
injected with simvastatin appeared normal when observed
on day 28 (Fig. 8B, C).
In the retina of an experimental PVR used as a positive-
control, apoptotic cells, which present TUNEL-positive
staining (green), were detected in the inner nuclear layer
and the outer nuclear layer (Fig. 8D). The eyes injected
with simvastatin had no apparent TUNEL-positive staining
in the retina when observed on day 28 (Fig. 8E).
The eyes injected with simvastatin had no apparent
ultrastructual changes in internal limiting membrane,
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FIG. 6. Inhibitory effects of simvastatin on vitreous-induced MLC phosphorylation and contraction of hyalocyte-containing collagen gels. A:
Starved hyalocytes were pretreated with 5 mol/l simvastatin for 30 min and subsequently treated with or without 400 l vitreous samples of
non-PVD (macular hole) or PVD (PDR and PVR) for 24 h. Total cell lysates were subjected to Western blot analysis with an antibody against
p-MLC. Lane loading differences were normalized by reblotting the membranes with an antibody against MLC and GAPDH. B: Signal intensity
ratios (p-MLC to GAPDH) were expressed as percentage of control intensity ratio. C: Hyalocytes were embedded in type I collagen gels (n  4).
After starvation and pretreatment with 5 mol/l simvastatin for 24 h, the collagen gels were stimulated with 400 l vitreous samples of non-PVD
or PVD. Five days after the stimulation, the gels were photographed. D: The diameter of the collagen gels was measured and expressed as
percentage of the average diameter of the control group. *P < 0.05.
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pared with the untreated control eyes (Fig. 8F). In other
parts of the retina, such as inner and outer nuclear layers,
photoreceptors, and retinal pigment epitheliums, there
were also no apparent changes.
DISCUSSION
Blindness is a devastating consequence of PVDs such as
PDR and PVR. Currently, the progression of these diseases
cannot be effectively prevented, and the treatment options
are limited to vitreoretinal surgery. An effective pharma-
cological treatment is thus urgently needed to complement
or potentially replace the surgical intervention. In the
current study, we show statins’ novel function in inhibiting
the Rho/Rho-kinase pathway, the contraction of collagen
gel, and the progression of experimental PVR, suggesting
the therapeutic potential of these compounds for the
treatment of PVDs.
Various cytokines, such as TGF-, connective tissue
growth factor, interleukin-6, and platelet-derived growth
factor (PDGF), are overexpressed in the vitreous and
membranes associated with PDR and PVR, and they
contribute to the pathogenesis of these diseases (15,37–
40). Among these cytokines, TGF-2 induces the transfor-
mation of retinal pigment epithelial cells or hyalocytes to
myoﬁbroblastic cells (18,41) and plays a key role in the
formation and contraction of proliferative membranes. In
this study, we conﬁrmed the overexpression of TGF-2i n
the vitreous from patients with PVD (PDR and PVR) and
showed that TGF-2 inhibition strongly suppressed the
vitreous-induced contraction of the collagen gels. This
indicates the possibility that TGF-2 is the dominant
contributor to the contraction of proliferative membrane
in the vitreous cavity. Thus, we focused on the role of
TGF-2 to investigate the mechanisms of membrane con-
traction. TGF-2 enhanced MLC phosphorylation in hya-
locytes that was responsible for the contraction of the
hyalocyte-containing collagen gels. We showed that sim-
vastatin suppressed TGF-2–induced MLC phosphoryla-
tion and collagen gel contraction in a dose-dependent
fashion by inhibiting GGPP-mediated translocation of Rho
to the plasma membrane, whereas no signs of cytotoxicity
were apparent.
Differences in the structural characteristics of statin
cause different levels of lipophilicity and possibly of
efﬁcacies and also cytotoxicity. Pravastatin is strongly
hydrophilic, and simvastatin is much more lipophilic than
pravastatin (42). Fluvastatin is also more lipophilic than
pravastatin; however, it is less lipophilic than simvastatin
(43). Although our comparison of the inhibitory effects of
various statins, simvastatin, ﬂuvastatin, and pravastatin,
revealed that simvastatin was more effective in reducing
MLC phosphorylation than the other statins under the
chosen experimental conditions, the results might vary at
other time points or concentrations. Further examination
is necessary to determine the order. Additionally, because
cerivastatin is more lipophilic than simvastatin (44), we
studied the effects of cerivastatin and simvastatin. Many
hyalocytes treated with 5 mol/l cerivastatin for 24 h
shrank and detached from the culture plates, whereas the
cells treated with 5 mol/l simvastatin remained morpho-
logically unchanged. However, at higher concentrations
(20 mol/l), some hyalocyte shrinkage was observed
even with simvastatin (data not shown). Cerivastatin is
known to be cytotoxic and induce apoptosis (45). The
morphological changes we observed in cerivastatin-
treated hyalocytes in our study suggest that this drug may
also be toxic to hyalocytes and promote their apoptosis.
Because the lipophilicity of lovastatin is similar to that of
simvastatin (42), we compared their effect and found the
inhibitory effect of simvastatin on MLC phosphorylation
and collagen gel contraction to be greater than that of 5
mol/l lovastatin for 24 h (data not shown).
Vitreous samples from patients with PDR and PVR
induced MLC phosphorylation and contraction of hyalo-
cyte-containing collagen gels, which were effectively inhib-
ited by simvastatin. It may appear surprising that not only
vitreous samples from patients with PVD but also those
from non-PVD patients induced MLC phosphorylation and
collagen gel contraction. However, this might be explained
by the fact that TGF-2 is expressed in vitreous samples of
patients with macular hole at high enough concentrations
to induce the observed phenomena. The concentrations of
TGF-2 in vitreous samples from patients with PVD (PDR
and PVR) were higher than in those from macular hole
patients. Therefore, in a concentration-dependent manner,
the inductions might be greater in the vitreous samples
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FIG. 7. Inhibitory effects of simvastatin on experimental PVR in rabbit
eyes. Rabbits underwent vitrectomy and intravitreal injection of ﬁbro-
blasts with and without simvastatin on day 0. The eyes were injected
with same contents of simvastatin on days 1, 3, 5, and 7 and examined
using indirect ophthalmoscope as long as 28 days after the surgery. A:
A representative vehicle-injected eye with PVR in stage 5, 28 days after
the surgery. Proliferative membranes were observed in the vitreous
cavity, causing a traction to the retina and retinal detachment. B:A
representative simvastatin-injected eye (15 mol/l) with PVR in stage
1. A thin proliferative membrane was observed, however, there was no
evidence of tractional retinal detachment. C: Clinical observations
were categorized according to the PVR classiﬁcation of Fastenberg et
al. (35). Stage 1, intravitreal membrane; stage 2, focal traction, local-
ized vascular changes, hyperemia, engorgement, dilation, and blood
vessel elevation; stage 3, localized detachment of medullary ray; stage
4, extensive retinal detachment, total medullary ray detachment, and
peripapillary retinal detachment; and stage 5, total retinal detachment.
F, vehicle; ,5mol/l simvastatin; Œ,1 5mol/l simvastatin. **P <
0.01, *P < 0.05; NS, not signiﬁcant compared with vehicle.
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without PVD. The concentrations of TGF-2 in some
vitreous samples from patients with macular hole were
higher than those with PDR and PVR. However, the
pathology of macular hole does not generally involve
proliferative membrane formation and tractional retinal
detachment. Occasionally, epiretinal membranes and reti-
nal folds accompany macular hole. Retinal folds are con-
sidered to be caused by the contraction of the epiretinal
membranes. TGF-2 concentrations in vitreous samples
from patients with macular hole may be high enough to
induce contraction of proliferative membranes, however,
because the epiretinal membrane in these patients does
not extend into the vitreous and is very thin; the expres-
sion of TGF-2 remains inconsequential.
MLC phosphorylation depends on the concentration of
TGF-2 (18); thus, the eyes with PVR having lower TGF-2
concentrations might represent a less severe pathology, or
remission, compared with those with higher TGF-2 con-
centrations. The occurrence of tractional retinal detach-
ment might depend on the presence or absence of
proliferative membranes and the concentration of TGF-2.
Although TGF-2–stimulated hyalocytes showed no sig-
niﬁcant change in MLC expression, those stimulated with
vitreous samples showed elevated MLC expression that
was inhibited by simvastatin treatment. The vitreous in-
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FIG. 8. Histological and physiological examinations of eyes injected with simvastatin. Rabbits received intravitreal injections of 0.1 ml vehicle
or vehicle with simvastatin (ﬁnal concentration of 5 or 15 mol/l simvastatin) on days 0, 1, 3, 5, and 7. A: Electroretinograms on day 28. A ﬂash
stimulus of intensity 1.30 log cd.s/m
2 was superimposed on a background luminance of 1.15 log cd/m
2. Light microscopy of the rabbit eye without
any treatment (B) and that of the eye injected with 15 mol/l simvastatin (C). Scale bar  100 m. Apoptotic and potentially necrotic cell death
detected by TUNEL in the section from positive control (rabbit PVR model on day 7 after its onset) (D) and in the section from the 15 mol/l
simvastatin-treated eye (E). Scale bar  50 m. Transmission electron microscopy of the rabbit eye without treatment (F) and that of the eye
injected with 15 mol/l simvastatin (G). Scale bar  10 m. (Please see http://dx.doi.org/10.2337/db08-0302 for a high-quality digital
representation of this image.)
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epithelial cells, glial cells, macrophages, and other intrav-
itreal cells (46). Thus, some cytokines other than TGF-2
might elevate the expression of MLC. Among the cytokines
found in the vitreous, insulin-like growth factor-I (IGF-I),
PDGF, and members of the endothelin family have been
shown to stimulate extracellular matrix contraction
(18,47,48). This study reveals a key role for TGF-2i nt h e
pathology of PVDs; however, it is possible that other
cytokines found in the vitreous might also be involved in
MLC phosphorylation and contraction of hyalocyte-con-
taining collagen gels. Because simvastatin almost com-
pletely inhibited the phenomena induced by vitreous
samples, it might also inhibit the effect of the other
cytokines, such as IGF-I, PDGF, and members of the
endothelin family and unknowns, which might be exerted
through the Rho/Rho-kinase pathway.
Simvastatin also prevented the development of PVR in
vivo. Proliferative membranes in simvastatin-injected
eyes, even if present, were very thin, whereas the mem-
branes in vehicle injected eyes with PVR in stage 4 or 5
were thick. Thus, simvastatin might have also an inhibitory
effect on the formation and growth of proliferative mem-
branes in addition to the cicatricial contraction of prolif-
erative membranes. However, after the end of the
simvastatin injections, even in the groups treated with
higher concentration of simvastatin (15 mol/l) the devel-
opment of PVR was not completely inhibited. This may be
due to a short biological half-life time of the compound in
the vitreous cavity. Therefore, to sustain a constant level
of intravitreal simvastatin concentration, frequent injec-
tions or a slow release drug delivery system might be
necessary.
Recent ﬁndings suggest that statins might have a num-
ber of beneﬁcial effects in the eye. Although the applica-
bility of statins on age-related macular degeneration is still
under investigation (49), statins are shown to have protec-
tive effects on primary open-angle glaucoma, a major
cause of blindness (50). The regulation of the intraocular
pressure (IOP) within a physiological range is of great
clinical importance. Statins are reported to downregulate
the IOP by increasing aqueous humor outﬂow via the
inhibition of Rho/Rho-kinase pathway in the trabecular
meshwork and the ciliary body (50).
In conclusion, simvastatin potently inhibits the Rho/
Rho-kinase pathway and thus might have therapeutic
potential in the prevention of cicatricial contraction of
proliferative membranes in vivo. This is the ﬁrst report
demonstrating the beneﬁcial effects of simvastatin in in-
hibiting the development of PVR. Statins might provide a
new strategy for the treatment and prevention of the
development of PVDs in humans.
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